MediciBio

Medici Bio is a pre-clinical stage biotechnology company dedicated to advancing the field of genetic medicine through next-generation lipid nanoparticle (LNP) delivery systems. The company's proprietary platform focuses on achieving extrahepatic delivery, enabling mRNA and other nucleic acid therapeutics to reach specific tissues and organs beyond the liver, such as the bone marrow, lungs, and spleen. By engineering novel ionizable lipids and utilizing high-throughput screening, Medici Bio aims to overcome the primary delivery challenges that currently limit the scope of RNA-based treatments. The company's technology is designed to support a wide range of applications, including cancer immunotherapy, protein replacement therapies, and vaccines for infectious diseases. Medici Bio operates as a spin-out from the University of Pennsylvania, leveraging cutting-edge research in bioengineering and nanotechnology.